Addex Therapeutics Ltd
SIX:ADXN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Addex Therapeutics Ltd
Pre-Tax Income
Addex Therapeutics Ltd
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Addex Therapeutics Ltd
SIX:ADXN
|
Pre-Tax Income
-CHf5.8m
|
CAGR 3-Years
43%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Pre-Tax Income
-$578m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-36%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Pre-Tax Income
CHf45.9m
|
CAGR 3-Years
56%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Pre-Tax Income
-CHf105.6m
|
CAGR 3-Years
50%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Pre-Tax Income
CHf5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Pre-Tax Income
-CHf19.9m
|
CAGR 3-Years
26%
|
CAGR 5-Years
-62%
|
CAGR 10-Years
N/A
|
|
Addex Therapeutics Ltd
Glance View
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 28 full-time employees. The company went IPO on 2007-05-22. The firm focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. The company also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
See Also
What is Addex Therapeutics Ltd's Pre-Tax Income?
Pre-Tax Income
-5.8m
CHF
Based on the financial report for Sep 30, 2025, Addex Therapeutics Ltd's Pre-Tax Income amounts to -5.8m CHF.
What is Addex Therapeutics Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
24%
Over the last year, the Pre-Tax Income growth was 12%. The average annual Pre-Tax Income growth rates for Addex Therapeutics Ltd have been 43% over the past three years , 24% over the past five years .
